-

01:14:39 PM

LIVE Real Time SRPT Stock Market News

SRPT - Sarepta Therapeutics Inc

03/23/21 8:30 AM

Nasdaq : SRPT

Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in

RHEA-AI

neutral

03/18/21 4:31 PM

Nasdaq : SRPT

Sarepta Therapeutics' Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration

Mean NSAD score improvement of 5.7 points from baseline was sustained

RHEA-AI

positive

03/15/21 8:30 AM

Nasdaq : SRPT

Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference

RHEA-AI

neutral

03/01/21 4:05 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments

- Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference - - Fourth quarter 2020 net product sales increased approximately 23% over the fourth quarter of 2019;

RHEA-AI

positive

02/26/21 7:12 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's

RHEA-AI

very positive

02/25/21 2:10 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces FDA Approval of AMONDYS 45(TM) (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE

RHEA-AI

very positive

02/24/21 4:30 PM

Nasdaq : SRPT

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences: Cowen 41st Annual

RHEA-AI

neutral

02/22/21 8:30 AM

Nasdaq : SRPT

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020 financial results after the Nasdaq Global Market closes on Monday, March 1, 2021. Subsequently,

RHEA-AI

neutral

02/04/21 4:30 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces Winners of the "Rare Lessons" Lesson Planning Competition

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the

RHEA-AI

very positive

01/29/21 8:30 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's

RHEA-AI

very positive

SRPT Chart

SRPT Data

industryPharmaceutical Preparation Manufacturing
websitehttps://www.sarepta.com/
ceoDouglas Ingram
security nameSarepta Therapeutics Inc
issue typecs
sectorManufacturing
sic code2834
tagsHealth Technology,Biotechnology,Manufacturing,Pharmaceutical Preparation Manufacturing
address215 1st St Ste 415
stateMassachusetts
cityCambridge
zip02142-1213
countryUS
phone16172744000

SRPT Description:

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of the end of 2019, the company has two approved drugs . Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.